Machine Learning Identifies Newly Diagnosed CLL Patients at Risk for Certain Outcomes
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
All articles by Christina Bennett, MS
Study Finds Real-World Outcomes Differ for Idelalisib in FL and CLL
The analysis revealed that Medicare beneficiaries had different treatment outcomes compared with the trial participants.
Circulating Tumor Plasma Cells Predict Progression in Myeloma
The presence of circulating tumor plasma cells by next-generation flow independently predicted disease progression after treatment in patients with multiple myeloma.
Older Patients With Follicular Lymphoma Benefit From Appropriate Therapy
For older patients with follicular lymphoma, receipt of appropriate therapy for this disease was associated with a significant gain in overall survival.
Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
A Salvage Therapy Option for Follicular Lymphoma Makes Headway
A response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone appeared effective as a salvage therapy for follicular lymphoma.
Real-World Insight on Patients With Multiple Myeloma: Results Drawn From a Large Health Plan
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma in Israel.
Mechanism Unearthed for Carfilzomib-Induced Reticulocytosis in Myeloma
Irreversible proteasome inhibitor carfilzomib appears to cause reticulocytosis in multiple myeloma by inhibiting terminal erythroid maturation.
Tumor-Initiating Cell Marker Identified in Myeloma
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
Next post in Myeloma
